Studies whether migraine medicines affect bladder symptoms and pelvic pain
Observes bladder symptoms and pain in adults with migraine receiving migraine medicines.
Plain-language title generated from the registry record
Registry title: Migraine Medication Effects on Urinary Symptoms
Key facts
- Where
- Cleveland, United StatesSee the site
Where in United States
- Cleveland Clinic - Main CampusCleveland, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Cleveland Clinic
- Trial code
- NCT06212661
- Record updated
- 19 October 2026
- Original description
A prospective observational cohort trial to study the effects of CGRP inhibitors (CGRPi) on lower urinary tract symptoms (LUTS) and bladder/pelvic pain. Candidates for either CGRPi or an alternative therapy for refractory migraines (OnabotulinumtoxinA (BoNTA) extracranial muscle injections) with baseline LUTS will be recruited. The investigators will assess LUTS and pelvic pain using validated symptom and quality-of-life questionnaires, pretreatment and at 3 months post-treatment follow-up, comparing change in symptoms based on treatment received.Read full original descriptionShow less
Migraine Medication Effects on Urinary Symptoms
A prospective observational cohort trial to study the effects of CGRP inhibitors (CGRPi) on lower urinary tract symptoms (LUTS) and bladder/pelvic pain. Candidates for either CGRPi or an alternative therapy for refractory migraines (OnabotulinumtoxinA (BoNTA) extracranial muscle injections) with baseline LUTS will be recruited. The investigators will assess LUTS and pelvic pain using validated symptom and quality-of-life questionnaires, pretreatment and at 3 months post-treatment follow-up, comparing change in symptoms based on treatment received.
Inclusion: Female Patients > 18 years; Refractory migraine, planned treatment with either:; CGRP inhibitors, including:; CGRP small molecule receptor antagonists ("gepants"): Ubrogepant, Rimegepant, Atogepant; CGRP monoclonal antibodies: Eptinezumab, Fremanezumab, Galcanezumab; CGRP receptor monoclonal antibodies: Erenumab; BoNTA extracranial muscle injections; Any of the following symptoms during the last month:; Urinating too often (frequency); Having a sudden urge to urinate that's difficult to hold back (urgency); Having a sudden urge to urinate and urine leaking before you make it to the toilet (urge incontinence).
Exclusion: Prior bladder BoNTA in last 12 months; Age < 18 years; CGRP treatment within the last 12 months or BoNTA (head / bladder) last 6 months; Patient (or medical decision-maker) unable to provide informed consent or unable to answer questionnaire; Unable to urinate, eg: post cystectomy, indwelling catheter, on intermittent self catheterization, ESRD w/ anuria.